Nagasu H, Yano Y, Kanegae H, et al. - The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on kidney function as seen in clinical trials compared with patients treated in clinical practice, with no evidence that the effects are influenced by the rate of kidney function decline or the presence of proteinuria.

• At baseline, the mean age at commencement of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, the mean eGFR was 68.1 mL/min per 1.73 m ², and proteinuria was present in 578 (28.0%) of included patients.

• SGLT2 inhibitor initiation was linked to a lower eGFR decline (difference in slope for SGLT2 inhibitors vs other drugs 0.75 mL/min/1.73 m ² per year [0.51 to 1.00]) during follow-up.

• One hundred three composite kidney outcomes occurred during a mean follow-up of 24 months: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group.

• The benefit of SGLT2 inhibitors was consistent regardless of proteinuria or the rate of eGFR decline prior to starting SGLT2 inhibitors.